Multiple myeloma: so much progress, but so many unsolved questions.
about
Current and emerging treatment options for patients with relapsed myelomaFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaMultiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.
P2860
Multiple myeloma: so much progress, but so many unsolved questions.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Multiple myeloma: so much progress, but so many unsolved questions.
@en
type
label
Multiple myeloma: so much progress, but so many unsolved questions.
@en
prefLabel
Multiple myeloma: so much progress, but so many unsolved questions.
@en
P2860
P1433
P1476
Multiple myeloma: so much progress, but so many unsolved questions.
@en
P2093
Stéphane Minvielle
P2860
P304
P356
10.3324/HAEMATOL.2013.083592
P577
2013-04-01T00:00:00Z